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To the Editor
Atopic Dermatits/Eczema (AD) is a common condition in childhood and is also suffered by
approximately 2–3% of adults (Eichenfield et al., 2014). Despite intense scientific
investigation into the genetics of AD, disease-linked loci are associated with a minority of
disease cases (Baurecht et al., 2015), leaving the etiology of spontaneous AD in question.
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To better understand the biology of AD and to identify protein markers of disease, we
applied quantitative techniques to identify differential Stratum Corneum (SC) proteins from
adult AD patients and normal individuals. Using discovery proteomics we identified over
1000 proteins in the SC, with over 200 differentially identified by condition. Selected
proteins were quantified with precise targeted methods. Technical details are described in the
Supplementary Materials and Methods (online).
Specifically, we profiled skin surface tape strip samples from 11 AD subjects at lesional and
nonlesional sites. These were compared with similar samples from 17 healthy subjects.
Combining all spectral evidence, we identified 1102 proteins at a 1% false positive error rate
(FPER). This represents the most comprehensive proteomic study of AD stratum corneum to
date (Broccardo et al., 2011, Sakabe et al., 2014). The full identification list can be found in
Supplementary File S1.
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A poorly characterized aspect of skin biology is the role of protein post-translational
modifications which are abundant in the outer layers of the epidermis. One such is
modification is citrullination (conversion of arginine to citrulline, also called deimination)
(Gyorgy et al., 2006). We included citrullination in our search parameters and filtered the
results to avoid false positives. We detected at least one citrullination site on 1005 proteins
(91% of those identified). The most citrullinated proteins were trichohyalin and filaggrin,
which are known to be heavily modified in vivo. For filaggrin, healthy and nonlesional
atopic skin were citrullinated on 78% and 75% of arginine residues, respectively. This
decreased to 62% in lesional skin, corresponding to a loss of modification on 56 residues. Of
the 386 proteins that were citrullinated in all conditions, 257 exhibit decreased fractional
citrullination in lesional sites compared to other conditions (Figure 1). Notably, trichohyalin,
an abundant hair protein not considered related to AD, showed a negligible difference by the
same comparison.
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We next analyzed differential proteins by two methods: Fisher’s exact test on identification
counts by condition and Student’s t-test on label-free quantification results for proteins
observed in greater than 10 samples (Figure 2A & 2B, repectively). 252 proteins were
differentially observed between healthy and AD samples (Figure 2A & Supplementary File
S1). Many were general plasma-related markers of inflammation. Preferentially observed in
AD included proteins related to inflammation and barrier function such as serpins A3, B4, &
B5, interleukin-1 receptor antagonist, interleukin-36 receptor antagonist, protein disulfide
isomerases, and S100s A4 & A6. In addition, 36 proteins were found as differentially
abundant via t-test (Figure 2B). These include inflammation-related proteins such as serpins
A1, B3, & B12 and S100s A8, A9, and A11. Proteins down-regulated in AD skin are
generally structural, including several keratins as well as filaggrin-2. Fillagrin-2 was only
annotated in 2009 (Wu et al., 2009) and mutations have been recently linked to persistent
AD (Margolis et al., 2014). When comparing nonlesional and lesional AD samples, 45
proteins are differentially observed (Figure 2A & Supplementary File S1). 16 are
preferentially found at the lesional site while 29 are observed more frequently in nonlesional
samples. The protein most preferentially identified at the lesional site was PYCARD, a key
regulator of inflammasome and activation and apoptosis (Martinon et al., 2002). One protein
found at the majority of nonlesional sites but only at 9% of lesional sites was SPINK5, a
gene with mutations linked to AD in Japanese patients (Kato et al., 2003).
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To confirm results from discovery LC-MS/MS, we targeted several AD-related proteins
using more sensitive and precise Selected Reaction Monitoring (SRM) mass spectrometrybased assays. These results support our shotgun LC-MS/MS label-free quantification, but
with increased sensitivity as expected. Caspase 14, beta-defensin, desmoglein-1,
desmoplakin, filaggrin, kallikrein-8, keratin 10, S100-A7, and S100-A9 all increase when
comparing healthy to atopic nonlesional skin. In addition, beta-defensin, filaggrin, S100-A7,
and S100-A9 further increase from nonlesional to lesional atopic skin. The only targeted
protein to show a significant decline is filaggrin-2, which decreases substantially from
nonlesional compared to lesional epidermis, in agreement with label-free quantification
above. Given the evidence for reduced abundance of filaggrin in atopic dermatitis from
several studies (Suarez-Farinas et al., 2011, Pellerin et al., 2013), our observation of
increased SRM signal in atopic skin may seem counterintuitive. Our label-free quantification
J Invest Dermatol. Author manuscript; available in PMC 2017 August 01.
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found filaggrin to be similar between healthy and AD (p=0.2, supplementary file S1). It is
important to consider that in the targeted SRM assay we are monitoring SRM signal from
the fully tryptic unmodified peptide, 3976HGSYGSADYDYGESGFR3992. In addition to the
mass shift introduced by citrullination, we observed that this modification typically results in
a missed cleavage at arginine, rendering the peptide invisible to the SRM assay deployed
here. Thus our observation is consistent with decreased citrullination on the endogenous
peptide as disease progresses. Indeed, the majority of evidence for filaggrin protein loss
comes from immunohistochemistry experiments where antibody epitopes are not always
characterized. It is possible that these epitopes are citrullinated, similar to those observed in
vivo for rheumatoid arthritis (Girbal-Neuhauser et al., 1999).
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While genetic factors tied to AD have been investigated in some detail, these account for a
minority of disease incidence (Baurecht and Hotze, 2015). Much focus has been directed
toward filaggrin loss-of-function mutations, however transcriptomic profiles stratified by
filaggrin mutation status demonstrate an up-regulation of this protein in wild-type AD
patients (Cole et al., 2014). We find a modest overlap between transcript and proteomic
differential markers (Supplementary information). Non-genetic potential disease factors
including microbiome diversity and epigenetic factors like DNA methylation have only
recently begun to be investigated (Kong et al., 2012, Rodriguez et al., 2014). The data
presented here demonstrate alterations in the protein post-translational modification profile
of patients with AD lesions which ultimately adds another dimension to the rich and
complex etiology of AD.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1.
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Fractional citrullination (modifications per arginine) for selected proteins. Many proteins
related to epidermal differentiation and homeostasis decrease in citrullination with
perturbation. The unrelated but highly citrullinated protein trichohyalin (TCHH) shows little
change with condition.
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Figure 2.

A) Differentially identified proteins (p < 0.05) from Fisher’s exact test. Bar lengths indicate
the observations by clinical condition. Proteins with the 5 lowest p-values are shown for
each condition. The full data table is in Supplementary file S2. B) Differentially abundant
proteins (adjusted p < 0.05) for healthy vs. atopic (nonlesional and lesional) samples. Bars
represent the difference in average Normalized Spectral Index by clinical condition. Positive
values indicate higher abundance in atopic samples and negative values indicate higher
abundance in healthy samples.
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